Communique from the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
Today, on May 26th, 2020, the Annual General Meeting (“AGM”) was held in ExpreS2ion Biotech Holding AB (“ExpreS2ion”). Below follows a summary of the resolutions. The resolutions were passed with the required majority.
Distribution of results
The AGM resolved to dispose the company's results according to the Board's proposal in the annual report. The AGM also decided that no dividend be paid for the financial year 2019.
Determination of the number of Board members, deputies, auditors and deputy auditors and determination of remunerations for the Board and the auditor
The AGM resolved that the board of directors shall consist of four ordinary board members and no deputy board member, and that board remuneration should amount to SEK 75,000 for the chairman of the board and with SEK 50,000 each for other ordinary board members. Furthermore the AGM decided that an auditor and no deputy auditor shall be appointed and that auditors' fees should be paid according to approved invoice in accordance with customary charging standards.
Election of Board members and auditor
The AGM resolved that Jakob Knudsen, Gitte Pedersen, Martin Roland Jensen and Allan Rosetzsky are re-elected as ordinary board members. It was also decided to re-elect Martin Roland Jensen as Chairman of the Board. Furthermore, the AGM decided that the company's auditor Ernst & Young Aktiebolag be elected until the end of the Annual General Meeting that will be held next financial year.
Decision to authorize the Board to decide on issues
The AGM decided to authorize the Board of Directors, on one or more occasions, with or without deviation from the shareholders' pre-emptive right, during the period until the next Annual General Meeting, to decide on the issue of shares and / or warrants that entitle the holder to subscribe for, or entail, the issue of, a maximum of a number of shares corresponding to an increase of the share capital of no more than ten (10) percent based on the total share capital of the company at the time of the Annual General Meeting 2020.
The issues shall be made at a market subscription price, subject to market-based issue discount, if applicable, and payment shall, in addition to cash payment, be made with a non-cash property or through set-off, or otherwise with terms.
Share issue decided on the basis of the authorization shall take place with the purpose of adding to the company working capital and / or capital for the development of the company's operations. If the Board decides on a new share issue with deviation from the shareholders' preferential rights, the reason shall be to provide the company with working capital, capital for the development of the company's projects and / or new owners of strategic importance for the company and / or acquisitions of other companies or businesses.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.